Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P22626
UPID:
ROA2_HUMAN
Alternative names:
-
Alternative UPACC:
P22626; A0A024RA27; A0A024RA61; A8K064; P22627; Q9UC98; Q9UDJ2
Background:
Heterogeneous nuclear ribonucleoproteins A2/B1 play a pivotal role in cellular processes, including mRNA processing, transport, and the stabilization of mature mRNAs. They form hnRNP particles, crucial for minimizing RNA tangling and ensuring efficient transcription and splicing. Additionally, these proteins are involved in the transport of specific mRNAs to the cytoplasm in neurons and oligodendrocytes, and play a role in innate immune response activation.
Therapeutic significance:
Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 2 is linked to variants affecting this protein. Understanding its role could lead to targeted therapies for this complex condition, highlighting its therapeutic significance.